Context Therapeutics Inc (CNTX) - News Archive

In a notable move to bolster its workforce, Context Therapeutics Inc. a clinical-stage biopharmaceutical company specializing in T-cell engaging bispecific antibodies for solid tumors, has announced the granting of nonq...

The Evolution of Cancer Treatment: Context Therapeutics Enters a New Era with Strategic Leadership and Innovative TherapiesIn an era where the quest for effective cancer treatments is both urgent and dynamic, Context Th...

: Context Therapeutics Inc. a biopharmaceutical company focused on developing innovative therapies for solid tumors, has announced the presentation of a poster highlighting its clinical asset, CTIM-76. This bispecific a...

Context to obtain exclusive development and commercialization rights to BA3362In a significant move within the biopharmaceutical industry, BioAtla, a global clinical-stage biotechnology company, and Context Therapeutics...

Context Therapeutics Inc., a pioneering company in the development of novel cancer therapies, has made a significant formal announcement regarding its leadership and clinical strategy. The recent appointments of Dr. Cla...

Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95 In a move that carries promising implications for cancer therapy, Context Therapeutics has announced the acquisition of a Phase 1-ready bispecific antibod...

Context Therapeutics has achieved a major milestone by gaining the U.S. Food and Drug Administration s (FDA) clearance for an investigational new drug (IND) application for its novel investigational cancer therapeutic,...

Context Therapeutics, a biopharmaceutical company focused on developing innovative cancer therapeutics, recently announced a successful private placement financing round, raising $100 million. This funding was supported...

Context Therapeutics recently reached a critical regulatory milestone, submitting its Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for its investigational compound CTIM-76. Aimed...